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T.E. Starzl. A.S. Rae. M. Trucco. P. Fontes. J.J. Fung. A.J. Demetris 
M y MAIN purpose today is to explain why HLA 
matching is so crucial for bone marrow transplanta-
1 ion on one hand. and yet so relatively IIl1imponallf for 
urgan transplantation on the other. 
THE ONE-WAY PARADIGM OF 
TRANSPLANTATION IMMUNOLOGY 
The one-way paradigm of transplantation immunology 
shown in Fig I was of course directly derived from our 
patron saints-Billingham. Brent. and Medawar. In their 
original model. I or in the defenseless parent to offspring FI 
hvhrid experiments. and after recipient cytoablation. the 
;Ivoidance of graft-vs-host disease (GYHD) after bone 
marrow or spleen cell transplantation was found to be 
dependent on good MHC compatibility. 
In analogous experiments. the same rules of histocom-
p;ltibility apply to immunologically defenseless recipients of 
Immunologically active whole organs as was emphasized by 
Billingham and Brent~ and demonstrated in detail for the 
Illtestine bv Monchik and Russell.' However. the usual 
immunologic context of whole organ transplantation is 
actually a mirror image of the bone marrow experiments. 
hut still involving a one-wav reaction. Now. the graft is the 
defenseless victim instead ;)1' being the aggresso;. 
This false conceptualization has been the paradigm of 
transplantation immunology for more than 40 years. In 
spite of its fatal intellectual flaw. the concept of an essen-
tially unidirectional immune reaction proved useful. It was 
translated into successful clinical bone marrow transplanta-
tion in I YfJiI by Robert Good and Fritz Bach. emphasizing 
ahove all the need for HLA compatibility if engraftment 
was to be accomplished without the complication of 
liVHD. 
THE 2-WAY IMMUNOLOGIC PARADIGM 
The one-way paradigm has never explained what we see 
daily in our whole organ clinics. exemplified by the failure 
of HLA matching to influence more profoundly the survival 
of whole organ grafts. This was recognized earlv bv trans-
plant surgeons who bv the time of the first succes~fulD clinical 
bone marrow cases' had already recorded thousands of 
successful whole organ transplantations (mostly kidneys) 
using continuous immunosuppression-without host pre-
conditioning. without dependence on MHC matching. and 
with no problems with GYHD. The avalanche of whole 
urgan cases began after a characteristic postoperative cycle 
II ;IS identified when azathioprine was systematically com-
Illncd with prednisone:' Kidney rejection could be reversed 
'lirprisingly easily with prednisone. More importantly. the 
Ilt:t:d later on for maintenance immunosuppression fre-
yuently declined. The same sequence has been seen since 
with all other organs transplanted and with all of the 
immunosuppressive regimens. Something appeared to have 
changed in the host. the graft. or both. But what? 
Thirty years and a revolution in immunology later. this 
question was answered. Donor leukoCYtes of bone marrow 
origin. which are part of the structure of all complex grafts 
(the so-called multilineage "passenger leukocytes"). had 
migrated from the organs and survived ubiquitously in the 
recipients.s," Thus. successful organ transplantation was a 
cryptic example of cell transplantation. whereby a small 
fragment of disseminated extramedullary donor bone mar-
row (shown in Figure 2 as a bone silhouette) was assimi-
lated into the overwhelmingly larger immunologic network 
of the host. The cdl movement was in both directions. In 
this bidirectiollal paradigm. the immunologic confrontation 
following whole organ transplantation involves a GYH as 
well as HYG reaction in which the two cell populations an: 
mutually cancelling. providing both can survive. The um-
brella of immunosuppression that covers both equally al-
lows this. 
The number of chimeric donor cells is small."·" Recent 
research has suggested how such a small numher of chi-
meric leukocyte~ can uown regulate the donor-specific 
reactivity of the vast army of recipient cells against which 
they are arrayed \ a veto clrcct: Fig 2). The uendritic cells of 
Steinman and Cohn 7 are thought to be key participants. 
With the paradigm of a two-way immune reaction. virtually 
every previously enigmatic problem seen clinically after 
experimental or clinical whole organ transplantation be-
comes either transparent or susceptible to experimental 
inquiry. 
THE BLINDFOLDING OF HLA 
This includes the loss or blunting of an HLA matching 
effect. With the two-way cancellation. it is easy to under~ 
stand how the expt!cted matching influence is blind folded. 
With each further level of histoincompatibility. the cancel-
ling effect is postulated to escalate both ways providing the 
process is chaperoned with an effective immunosuppressive 
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One-Way Paradigm (Spleen) 
GVH 
umbrella. with a consequent dwindling of the matching 
effect as donor-specific and recipient-specific nonreactivity 
evolves. In this context. suppressor and veto cells. changes 
in cytokine profiles. and the development of enhancing 
antibodies are derivative from the primary event of mutual 
cdl engagement (Fig 2). 
The importance of the sponruneous chimerism and its 
densitv has been demonstrated by Robert Keenan and 
Adriana Zeevi (Universitv of Pittsburgh). They stratitied 15 
lung transplant recipients. with follow-up of I to 5 years. 
into a clinical and histopathologically favorable group of 
eight with no bronchiolitis obliterans and seven who had 
this ominous tinding of chronic rejection. The patients 
without bronchiolitis llbliterans had dense chimerism-
positive in eight of eight lymph nodes. seven of eight skin 
biopsies. and six of eight blood samples.x Chimerism also 
was demonstrable in several patients of the less favored 
group but less regularlv and with a generally lower quanti-
tative grade. Using the stored donor spleens. donor-specitic 
nonreactivity was demonstrated in all but one of the highly 
chimeric recipients. but in only two of the less favored 
group. These results had no correlation with the preopera-
tive HLA match. 
In addition to explaining whv the HLA matching effect is 
hlind folded. this bidirectional mechanism explains why 
GVHD does nO[ develop after liver. intestinal. multivis-
cera!. and heart-lung transplantation. It also explains why 
all whole organs have the inherent capabilitv of toleroge-
nicitv. Calne's brilliant studies with Sells in pigs" and with 
t 
Defenseless Recipient 
Blilingham-Brent-Medawar 
Cytoablation (x-ray, drugs) 
Parent-. Offspring F1 Hybrid 
Fig 1. Transplant model used 
in the first demonstration by 
Billingham. Brent. and Med-
awar' to demonstrate the ac-
quisition of immunologic toler-
ance. 
Zimmerman and Kamada in rats of the leukocyte-rich liver 
provided the most clear examples-called hepatic tolero-
genicity. However. Corry et al lo and Russell et al" showed 
long ago the tolerogenicity of even the leukocyte-poor heart 
and kidney in mice but ollly with less difficult MHC barriers. 
Finally. the once vast gap between the bone marrow and 
whole organ transplantation tields was further closed when 
it was shown bv the teams of Donnall Thomas in Seattle 12 
and others l.1 u~ing sensitive detection techniques that there 
is a trace population of recipient cells in patients whose 
hone marrow was previously thought to have been com-
pletely replaced. Thus. in these patients. as in whole organ 
recipients. the appearance of MHC restricted veto and 
suppressor cells. enhancing antibodies. and changes in 
cytokine profiles could be construed as by-products of and 
accessory to the seminal event of mixed chimerism. similar 
to the depiction of Fig 2. The difference in principle 
hetween the bone marrow and whole organ recipients turns 
on which of the coexisting cell populations is present at 
trace levels. 
DONOR LEUKOCYTE AUGMENTATION 
:\t a practical clinical level. the observations establishing 
the two-way paradigm exposed a perioperative window of 
llpportunity. which is not HLA dependent during which 
unahcred HLA incompatible hone marrow can be en-
graltcd safely in organ recipients without recipient condi-
tioning. without T-cell depletion. and with no deviation 
, 
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Fig 2. Bidirectional mecha-
nism of whole organ graft ac-
ceptance involVing a graft-vs-
host (GVH) reaction by the bone 
marrow denved donor leuko-
cytes in the graft that are pitted 
against the whole recipient im-
munologic apparatus (host-vs-
graft [HVGJ rejection). For con-
ventional whole organ clinical 
transplantation. the recipient IS 
not preconditioned. 
Not Quite 
'efenseless Graft 
Veto/Suppressor Cells 
Cytokine Profile Changes 
Enhancing Antibodies 
HVG (Rejection) 
from the standard practices of postoperative immunosup-
pression used in whole organ centers. This has been done in 
Pittshurgh with the infusion of 3 x lOx/kg unaltered donor 
hone marrow cells perioperatively in M consecutive pri-
mary recipients of cadaveric kidneys. livers. hearts. and 
11In!!s (Fig 3). Immunosuppression was with the standard 
\tralc!,'Y developed a third of century ago with azathioprine 
and prednisone but now with the combination of FK 501i 
and prednisone instead. 
All 1i4 of these patients are well except for a cardiac 
recipient who died with a normal heart of nonimmunologic 
complications 9 months after transplantation (Table I). 
Chimerism. estimated to be more than I UOO times greater 
than that occurring spontancously. could bc reliably pro-
duced and sustained. The first 18 of these patients were 
recently reported in The Lancer. 14 The familiar events were 
ohserved of crisis and recovery that are also seen in 
Illlnmarrow augmented control recipients. The notable 
~fhsence of serious GYHD. and the presence Dt well-
Ilinctioning grafts in all of the patients. has marked these 
rC'ciplents as an advantaged cohort. Although drug weaning 
111 these densely chimeric patients is expected to take 
\everal years. they are the tirst recipients to undergo HLA 
mismatched cadaveric whole organ transplantation with the 
reasonable prospect of eventually becoming drug free. 
Unconditioned 
Recipient 
TERASAKI'S SEMINAL OBSERVATION 
In closing. it is worth reflecting on the previous work of Paul 
Terasaki. who in 1970 announced at the Third Transplan-
tation Congress at The Hague that tissue typing did not 
accurately predict outcome atter kidney transplantation 
except when there was a perfectlv matched donor (unpuh-
lished manuscript). This courageous report was treated as a 
scandal by the HLA community and was the beginning of a 
dispute that has never come to closure. Now we can explain 
Terasaki"s results as well as those obtained by us from a 
6-year prospecti\'e trial of HLA matching for kidney transplan-
tation carried out in collaboration with Terasaki at the Uni-
versity of Colorado heTWeen 19M and 1970. 15 This was the 
first such matching trial ever done. When matching proved to 
he non predictive of outcome except when there was a perfect 
match. we were stunned. because we had no explanation. 
Ironically. the explanation was published as early as 1953 
at least in concept. hy Simonsen-one of this years' Med-
awar laureates-who wrote: " ... our only real hope of 
making homotransplantation of the kidnev a clinically 
feasible procedure ... must actually be based on the follow-
ing conditions: First. that the most important individual-
specific antigens are shared by the kidney and the blood 
cells. so that a gross biological incompatibility can be 
eliminated by detailed blood determination. Second. that 
-~----------~-I---
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Slowly Evolving Donor 
and Recipient-Specific 
Nonreactivity 
(Bidirectional Tolerance) 
Fig 3. Strategy for donor leu-
kocyte augmentation in recipi-
ents of whole organ allografts. 14 
The bone marrow is given at the 
time of the surgical transplant 
procedure. 
the kidney's defense reaction against the recipient's anti-
bodies and/or antigens can check a less significant biological 
incompatibility ... and thus provide a more or less com-
plete adaptation to the recipient.'''/> As it has turned out. 
the tirst of these conditions. histocompatibility matching. is 
apparently less important in the whole organ field than the 
second which is the primitive outline of what we now call 
the two-way paradigm. 
CONCLUSIONS 
As in Edgar Allen Poe's ( IX(N to IX4lJ) famous short story. 
n,e Pllr/oilled Lmer. the reason for the failure of an HLA 
matching etfect was not found for such a long time because it 
Table 1. Whole Organ Transplantation With 3 x 108 /kg Bone 
Marrow Cells (December 14, 1992 to August 5,19941 
SUlVlval 
Organ Pallent Graft 
Kidney 17 17 
Kidney .,. Islets 6 6 
Kidney .,. pancreas 2 2 
Liver 28 28 
Liver - Islets 1 1 
Heart 8 r 
Lung 2 2 
Total 64 63 
Nole: The torst 18 pallents were reponeo In The Lancer. July 17. 1994. There 
was no nost conOlll00ln9. 
'NonlmmunOloglc oeatn. 9 montns-carOfac aHogren normal. 
was hidden in such obvious locations-throughout the body of 
the recipient in the form of donor chimeric cells (Fig 2). 
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